Thoracic mesenchymal malignant tumors and programed cell death ligand ‐1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eightmalignant mesotheliomas

ConclusionThe present study showed that sarcomatoid carcinoma had a higher PD-L1 expression compared to non-small-cell lung cancer and that both PSC and MPM tended to exhibit PD-L1 positivity in the sarcomatoid compartment. Moreover, while immune checkpoint inhibitors may somewhat prolong the prognosis of both tumors, further studies with a larger cohort are necessary to confirm our results.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research

Related Links:

Pemetrexed has been approved by United States Food and Drug Administration (US FDA) in combination with platinum for the treatment of advanced non-squamous non-small cell lung carcinoma (NSCLC)(1) and malignant mesothelioma(2). Maintenance therapy after induction chemotherapy with pemetrexed has been shown to prolong progression-free survival (PFS) and overall survival (OS). In the PARAMOUNT trial, for patients who had objective response or stable disease after four cycles of doublet chemotherapy, maintenance pemetrexed improved the PFS by 1.3 months and OS by 2.9 months, when compared with placebo (3).
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
A novel clinical trial involving the immunotherapy combination of Opdivo and Yervoy will open soon in Chicago. The goal is to study the drugs’ efficacy when added to surgery for patients with peritoneal mesothelioma cancer. The single-center, phase II clinical trial follows a recent report detailing the impressive three-year effectiveness of the drug combination when used for unresectable pleural mesothelioma. Bristol Myers Squibb manufactures Opdivo and Yervoy, known generically as nivolumab and ipilimumab. The U.S. Food and Drug Administration approved the combination for pleural mesothelioma in 2020, making ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Adding the drug ramucirumab to gemcitabine chemotherapy worked especially well in a recent clinical trial involving second-line treatment for patients with pleural mesothelioma. Ramucirumab, an immunotherapy drug also known by the brand name Cyramza, is a monoclonal antibody that works by targeting and restricting a protein that stimulates blood vessel growth within tumors. Impressive results in the phase II clinical trial moved the drug combination closer to filling the long-standing void for a second-line mesothelioma treatment. The Lancet Oncology recently published results of the study, which was conducted in ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusion: Combining EPD with HITOC can be performed in patients with either pleural mesothelioma or pleural metastases resulting in low perioperative morbidity and mortality as well as remarkable local tumor control.Respiration
Source: Respiration - Category: Respiratory Medicine Source Type: research
Pemetrexed is a multi-targeted antifolate that inhibits three enzymes used in purine and pyrimidine synthesis — thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). Pemetrexed has been approved by United States Food and Drug Administration (US FDA) in combination with platinum for the treatment of advanced non-squamous non-small cell lung car cinoma (NSCLC) (1) and malignant mesothelioma (2). Studies showed that pemetrexed has equivalent efficacy to docetaxel but is associated with significantly less toxicity (1,3).
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Conditions:   Non Small Cell Lung Cancer;   Non-squamous Non-small-cell Lung Cancer;   Urothelial Carcinoma;   Malignant Mesothelioma Interventions:   Drug: Cabozantinib;   Drug: Pemetrexed Sponsor:   Augusta University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Asbestosis | Cancer | Cancer & Oncology | Carcinoma | Lung Cancer | Mesothelioma | Non-Small Cell Lung Cancer | Study